Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.

[1]  L. Gaohua,et al.  Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations. , 2019, Drug discovery today. Technologies.

[2]  M. Shalaeva,et al.  Experimental lipophilicity for beyond Rule of 5 compounds , 2019, Future Drug Discovery.

[3]  Asher Mullard,et al.  First targeted protein degrader hits the clinic , 2019, Nature Reviews Drug Discovery.

[4]  Guangju Ji,et al.  A chemical approach for global protein knockdown from mice to non-human primates , 2019, Cell Discovery.

[5]  Shaomeng Wang,et al.  Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. , 2019, Journal of medicinal chemistry.

[6]  Danhui Ma,et al.  The PROTAC technology in drug development , 2019, Cell biochemistry and function.

[7]  M. Koegl,et al.  Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7 , 2018, Journal of medicinal chemistry.

[8]  C. Crews,et al.  MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. , 2018, Cancer research.

[9]  Michael D Shultz,et al.  Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs. , 2018, Journal of medicinal chemistry.

[10]  Roberto A Barrero,et al.  Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development. , 2019, Biotechnology advances.

[11]  Philipp M Cromm,et al.  Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation. , 2018, Journal of the American Chemical Society.

[12]  David M. Wilson,et al.  Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. , 2018, ACS chemical biology.

[13]  Liwu Fu,et al.  Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs , 2018, EBioMedicine.

[14]  Martin C Fillmore,et al.  Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach. , 2018, ACS chemical biology.

[15]  Weiping Tang,et al.  Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. , 2018, Bioorganic & medicinal chemistry letters.

[16]  Liu Liu,et al.  Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. , 2018, Journal of medicinal chemistry.

[17]  Graham M. West,et al.  Delineating the role of cooperativity in the design of potent PROTACs for BTK , 2018, Proceedings of the National Academy of Sciences.

[18]  M. Waring,et al.  Practical application of ligand efficiency metrics in lead optimisation. , 2018, Bioorganic & medicinal chemistry.

[19]  Hongying Gao,et al.  PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies , 2018, Cell Research.

[20]  Bradley C Doak,et al.  Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space. , 2018, Current opinion in chemical biology.

[21]  J. Byrd,et al.  Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. , 2018, Biochemistry.

[22]  Yuzong Chen,et al.  Phthalimide conjugations for the degradation of oncogenic PI3K. , 2018, European journal of medicinal chemistry.

[23]  P. Jänne,et al.  Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). , 2018, Journal of medicinal chemistry.

[24]  Vasanthanathan Poongavanam,et al.  Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5. , 2018, Journal of medicinal chemistry.

[25]  Shanshan Gu,et al.  PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery , 2018, BioEssays : news and reviews in molecular, cellular and developmental biology.

[26]  James E. Bradner,et al.  The dTAG system for immediate and target-specific protein degradation , 2018, Nature Chemical Biology.

[27]  N. Gray,et al.  Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8. , 2018, ACS medicinal chemistry letters.

[28]  M. Naito,et al.  Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation , 2018, The Journal of Biological Chemistry.

[29]  H. Handa,et al.  Structural basis of thalidomide enantiomer binding to cereblon , 2018, Scientific Reports.

[30]  I. Churcher.  Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones? , 2017, Journal of medicinal chemistry.

[31]  P. Workman,et al.  Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766) , 2017, Journal of medicinal chemistry.

[32]  R. Young,et al.  Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. , 2017, Nature chemical biology.

[33]  Dennis L. Buckley,et al.  A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. , 2017, Cell chemical biology.

[34]  Jing Wang,et al.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. , 2017, Cell chemical biology.

[35]  M. Wendt,et al.  Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. , 2017, Journal of medicinal chemistry.

[36]  Yevgeniy V. Serebrenik,et al.  Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. , 2017, Journal of medicinal chemistry.

[37]  M. Naito,et al.  Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands. , 2017, Journal of medicinal chemistry.

[38]  A. Ciulli,et al.  Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds , 2017, Journal of medicinal chemistry.

[39]  J. McCarter,et al.  A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. , 2017, Journal of medicinal chemistry.

[40]  J. Ovádi,et al.  Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). , 2017, Journal of medicinal chemistry.

[41]  Liu Liu,et al.  Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression , 2017, Journal of medicinal chemistry.

[42]  C. Crews,et al.  Small-Molecule Modulation of Protein Homeostasis. , 2017, Chemical reviews.

[43]  Sandeep Rana,et al.  Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). , 2017, Chemical communications.

[44]  Yoshiyuki Ogino,et al.  LC-MS/MS and chiroptical spectroscopic analyses of multidimensional metabolic systems of chiral thalidomide and its derivatives. , 2017, Chirality.

[45]  Daniel G. Anderson,et al.  Advances in the delivery of RNA therapeutics: from concept to clinical reality , 2017, Genome Medicine.

[46]  C. Crews,et al.  Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy. , 2017, ACS chemical biology.

[47]  D. Lamont,et al.  Structural basis of PROTAC cooperative recognition for selective protein degradation , 2017, Nature chemical biology.

[48]  M. Naito,et al.  In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)* , 2017, The Journal of Biological Chemistry.

[49]  Craig M. Crews,et al.  Induced protein degradation: an emerging drug discovery paradigm , 2016, Nature Reviews Drug Discovery.

[50]  Ulf Norinder,et al.  Structural and conformational determinants of macrocycle cell permeability. , 2016, Nature chemical biology.

[51]  C. Crews,et al.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer , 2016, Proceedings of the National Academy of Sciences.

[52]  Bradley C Doak,et al.  How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets. , 2016, Journal of medicinal chemistry.

[53]  Eunhwa Ko,et al.  Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. , 2016, Angewandte Chemie.

[54]  J. Lieberman,et al.  Knocking down disease: a progress report on siRNA therapeutics , 2015, Nature Reviews Genetics.

[55]  I. E. Smith,et al.  Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.

[56]  C. Bennett,et al.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. , 2015, Advanced drug delivery reviews.

[57]  Dennis L. Buckley,et al.  Selective Target Protein Degradation via Phthalimide Conjugation , 2015 .

[58]  C. Crews,et al.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.

[59]  A. Ciulli,et al.  Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.

[60]  Li-juan Ji,et al.  CRISPR-Cas9: a new and promising player in gene therapy , 2015, Journal of Medical Genetics.

[61]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[62]  T. Hoffmann,et al.  Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.

[63]  Fabrizio Giordanetto,et al.  Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. , 2014, Chemistry & biology.

[64]  Michael J Shapiro,et al.  EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides. , 2014, ACS medicinal chemistry letters.

[65]  J. Kosek,et al.  Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration , 2012, Cancer Chemotherapy and Pharmacology.

[66]  Julien Michel,et al.  Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction , 2012, Journal of the American Chemical Society.

[67]  M. Varma,et al.  Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability , 2012 .

[68]  Minoru Ishikawa,et al.  Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. , 2010, Journal of the American Chemical Society.

[69]  C. Crews,et al.  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.

[70]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[71]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification , 2007, J. Chem. Inf. Model..

[72]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[73]  Michael I. Wilson,et al.  Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[75]  Gordon M. Crippen,et al.  Prediction of Physicochemical Parameters by Atomic Contributions , 1999, J. Chem. Inf. Comput. Sci..

[76]  P. Carrupt,et al.  Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. , 1998, Chemical research in toxicology.

[77]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[78]  K. Leong,et al.  Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-beta-cyclodextrin. , 1992, Journal of pharmaceutical sciences.